Tesamorelin and Visceral Fat: FDA-Approved Phase 3 Results

Tesamorelin holds a distinction no other peptide in the fat-loss category can claim: FDA approval for visceral fat reduction, granted in November 2010 under the brand name Egrifta. The clinical dataset behind that approval — a pooled analysis of two Phase 3 trials — provides some of the most rigorous human evidence for any research peptide.

The Trial

The 2010 pooled analysis combined two multicenter, double-blind, placebo-controlled Phase 3 trials enrolling 806 HIV-positive adults on antiretroviral therapy who had developed excess abdominal fat (lipodystrophy) — a common side effect of HIV treatment. Participants received tesamorelin 2 mg/day or placebo via subcutaneous injection for 26 weeks.

Key Results

At 26 weeks:

• 15.4% mean reduction in visceral adipose tissue (VAT) in the tesamorelin group vs. a slight increase (+2 cm²) in placebo
• 69% of subjects in the tesamorelin group achieved a ≥8% reduction in VAT vs. 33% placebo
• Significant improvements in triglycerides and IGF-1 levels
• VAT reduction was sustained through 52 weeks in an extension phase

"Tesamorelin produced significant and sustained reductions in visceral adipose tissue with a generally favourable safety profile." — Falutz et al., JCEM 2010

How Tesamorelin Works

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary, stimulating the natural pulsatile release of growth hormone. Elevated GH then promotes lipolysis — the breakdown of fat — with a preferential effect on visceral (deep abdominal) fat compared to subcutaneous fat.

Unlike exogenous HGH, tesamorelin stimulates endogenous GH secretion, preserving the normal feedback loop. This is the reason its safety profile in the trials was manageable.

Safety

The most common adverse events were injection-site reactions, fluid retention (oedema), and arthralgia — consistent with increased GH activity. Glucose and insulin levels were monitored closely: there was no clinically meaningful worsening of glucose tolerance in the trials, which contributed to the FDA's approval decision.

Relevance Beyond HIV

While the FDA approval is specifically for HIV-associated lipodystrophy, the mechanism — stimulating endogenous GH to reduce visceral fat — is not disease-specific. Research interest in tesamorelin for general visceral adiposity and metabolic syndrome continues, with investigator-initiated studies ongoing as of 2026.